Clinical Trial Search

Primary: Neurological Assessment for Motor Function and Reflexes/Sensory — 0; 0 participants

Primary: Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level — 49.7 Percentage of participants

Primary: 7-day Point Prevalence Abstinence From Smoking at 6 Months — 21; 16; 15; 14 Number of abstinent participants — p=>0.05

Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…

Primary: Change From Baseline in KOOS4 (Knee Injury and Osteoarthritis Outcome Score) — 18.2; 7.1 units on a scale

Primary: Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability — 3; 3; 6; 3 participants

Primary: Progression-free Survival — 8.0; 8.7; 8.8 Months — p=0.0318

Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h

Primary: Sum of All Symptoms in Viruspositive Persons — 52; 52; 54; 56 units on a scale — p=<0.037

Primary: Summary of Nilotinib Non-compartmental PK Parameters: Cmax — 405.111; 402.715 ng/mL

Primary: Change in KOOS4 From Baseline (Knee Injury and Osteoarthritis Outcome Score) — 16.0; 32.5 units on a scale

Primary: Median Investigator-Assessed Progression-free Survival (PFS) Time (Months) From Randomization to Date of First Tumor Progression or Death Due to Any Cause - Randomized…

Primary: FEV1, Late Asthmatic Response (LAR) - Pre-treatment — 0.814; 1.01 ratio

Primary: Percentage of Participants Who Were Disease-Free for at Least 12 Months After Initial Diagnosis — 73.1; 80.6 percentage of participants

Primary: Percentage Change From Baseline in the LDL-C/HDL-C Ratio — -50.9; -53.0; -37.6; -42.4 Percentage Change — p=<0.001